Squarepoint Ops LLC Makes New Investment in Chimerix, Inc. (NASDAQ:CMRX)

Squarepoint Ops LLC purchased a new position in shares of Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 37,297 shares of the biopharmaceutical company’s stock, valued at approximately $130,000.

A number of other institutional investors also recently bought and sold shares of CMRX. Bender Robert & Associates acquired a new position in Chimerix in the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new position in Chimerix in the 4th quarter valued at about $59,000. Jane Street Group LLC acquired a new position in Chimerix in the 4th quarter valued at about $62,000. Diadema Partners LP acquired a new position in Chimerix in the 4th quarter valued at about $101,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Chimerix in the 4th quarter valued at about $183,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CMRX has been the topic of several recent analyst reports. HC Wainwright reiterated a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reiterated a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Wall Street Zen initiated coverage on Chimerix in a research report on Sunday, May 18th. They set a “sell” rating on the stock.

Chimerix Price Performance

NASDAQ:CMRX opened at $8.54 on Tuesday. The business’s 50-day moving average is $8.54 and its two-hundred day moving average is $5.94. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $8.55. The firm has a market capitalization of $801.09 million, a PE ratio of -9.09 and a beta of -0.17.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. Equities analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.